Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ProKidney Corp. - Class A Ordinary Shares (NQ: PROK )

1.510 +0.050 (+3.42%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ProKidney Corp. - Class A Ordinary Shares

< Previous 1 2 3 4 Next >
ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
From ProKidney
Via GlobeNewswire
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
From ProKidney
Via GlobeNewswire
ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
From ProKidney
Via GlobeNewswire
PROK Stock Earnings: ProKidney Beats EPS for Q2 2024
PROK stock results show that ProKidney beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
PROK Stock Earnings: ProKidney Reported Results for Q4 2023
ProKidney just reported results for the fourth quarter of 2023. 
Via InvestorPlace
PROK Stock Earnings: ProKidney Beats EPS for Q1 2024
PROK stock results show that ProKidney beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024
From ProKidney
Via GlobeNewswire
ProKidney to Participate in the UBS Virtual Organ Restoration Day
From ProKidney
Via GlobeNewswire
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
From ProKidney
Via GlobeNewswire
ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From ProKidney
Via GlobeNewswire
ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
From ProKidney
Via GlobeNewswire
Over $30M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
From ProKidney
Via GlobeNewswire
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
From ProKidney
Via GlobeNewswire
Why Contango Ore Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Calavo Growers Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth checking out on Tuesday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
From ProKidney
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Pre-market stock movers are worth diving into on Monday and we have all of the latest news worth knowing about this morning! 
Via InvestorPlace
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
From ProKidney
Via GlobeNewswire
ProKidney to Participate in the Jefferies Global Healthcare Conference
From ProKidney
Via GlobeNewswire
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
From ProKidney
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
From ProKidney
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.